IL-8 level based method of predicting the outcome of colon cancer treatment
AssigneeSanofi
InventorsMarielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
Claims10
A method for treating a patient with colon cancer, colorectal cancer or a rectal cancer with 1 mg/kg-10 mg/kg aflibercept, or ziv-aflibercept, 200 mg/m2-600 mg/m2 folinic acid, 2000 mg/m2-4000 mg/m25-fluorouracil (5-FU) and either 85 mg/m2 oxaliplatin or 100 mg/m2-300 mg/m2 irinotecan to the patient, wherein a biological sample obtained from the patient has an interleukin-8 (IL-8) level that is lower than a reference level of IL-8.
Dependencies are inferred from the claim text.